Fig. 1From: IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapyA Schematic of the study design and cohort sizes. These panels visualize data from the Discovery cohort (Validation data is in supplemental figures). B Biological processes enriched in the genes differentially expressed between matched primary and recurrent GBMs. C Per-patient normalized enrichment scores (NES, top plot) and false discovery rates (FDR, bottom plot) for top-scoring promoter-binding factors associated with longitudinal gene expression changes. D Heatmap of the longitudinal fold change in expression for each patient (columns) for the JARID2 binding sites genes (JBSgenes) in the leading edge of > 50% of patients (LE50 genes, rows). Patients separate into Up (NES > 0) and Down (NES < 0) responders irrespective of RNAseq library preparation approach. E Patients are plotted, colored by JBSgenes NES, according to principal components 1 (PC1) and 2 (PC2) of their whole transcriptome longitudinal fold change in expression. F Heatmap of the longitudinal fold change in expression for each patient (columns) for the largest 100 positive and largest 100 negative weighted genes of PC1 from panel E (rows). Whether each gene is a JBSgene is also indicated. G Each gene is plotted according to its -log10p-value result of separate differential expression analyses (DEA) in matched recurrent vs primary tumors in Down (x-axis) and Up (y-axis) responders. Left plot: genes colored according to whether they are JBSgenes or, more specifically, LE50 and LE70 genes. Right plot: genes colored according to whether they are in the top 100 or 1000 genes ranked by the absolute value of PC1 from the analysis in panel E. H Plotting patients according to their JBSgene NES and PC1 score from panel E clearly separates Up and Down respondersBack to article page